中国·金沙-www.8888js.com|官方网站-BEST LOBBY

Be the most trusted biotech company

2024-04-29

Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
2024-04-26

Henlius Trastuzumab Receives FDA Approval in the United States
2024-04-25

Henlius to Showcase Latest Results of Serplulimab at 2024 ASCO
2024-04-23

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018
2024-04-17

IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI for the First-Line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients Approved by NMPA
2024-04-17

Henlius Releases 2023 ESG Report Pursuing Sustainable Development with Patient-centricity
2024-04-10

Results of Exploratory Biomarker Analysis of Pivotal Clinical Trial ASTRUM-005 of Serplulimab Initially Released at AACR 2024
2024-04-08

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
2024-03-21

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved